BioCryst Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 84   

Articles published

BCRX 13.21 -0.42 (-3.08%)
price chart
Can BioCryst Pharmaceuticals, Inc. (BCRX) Stop The Ebola Outbreak?
biotechnology Jay Taylor: I grew up in Reston, Virginia. Unless you're from the Washington D.C. area I doubt you've ever heard of it.
Biocryst Pharmaceuticals (BCRX) Highlighted As Today's Perilous Reversal ...
Stocks On the Move: BioCryst Pharmaceuticals, Inc., ITT Educational Services ...  Schaeffers Research (blog)
Related articles »  
BioCryst Pharma Inc (BCRX) Coverage Initiated By JP Morgan With Overweight
BioCryst Pharmaceuticals, Inc. (BCRX) was initiated with a 'Overweight' and it was given a $20.00 price target at JP Morgan (JPM) in a research report issued to clients on Friday.
Notable Analyst Actions: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ...  Financial Wired
Friday's Hot Stocks: Mercadolibre Inc (MELI), BioCryst Pharmaceuticals ...  Investor Wired
Related articles »  
Should Investors Really Be Chasing Potential Ebola Treatments?
Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR) and BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) are two such companies with studies taking place that could treat Ebola.
As Ebola virus spreads, investors bet on potential cures  The Gazette: Eastern Iowa Breaking News and Headlines
Ebola Drug by Tekmira May Be Used on Infected Patients  Bloomberg
Related articles »  
BioCryst Pharmaceuticals (BCRX) Edging Higher on Additional NIAID Funding
BioCryst Pharmaceuticals, Inc. (BCRX) shares are edging higher in early trading on Wednesday following news that $4.1 million additional National Institute of Allergy and Infectious Diseases [NIAID] funding will be given to the company to advance ...
BioCryst Receives Additional NIAID Funding to Advance Development of ...  CNNMoney
U.S. Government Advances Development Of BioCryst's Potential Ebola Drug  Business Insider
Related articles »  
Trader's Buzzers - BioCryst Pharmaceuticals, Inc. (BCRX), Uranium Energy Corp ...
Birmingham, West Midlands - (TechSonian) - 25 August 2014 - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised additional options to conduct Phase 1 clinical ...
Why Making Dramatic Moves? � NVIDIA Corporation (NVDA), BioCryst ...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) gained more than 8% after analysts at JP Morgan launched coverage on the stock with a Overweight rating and a $20 price target.
Related articles »  
BioCryst Pharmaceuticals Receives Consensus Rating of "Buy" from Analysts ...
BioCryst Pharmaceuticals logo BioCryst Pharmaceuticals (NASDAQ:BCRX) has earned a consensus rating of �Buy� from the twelve brokerages that are covering the company, Stock Ratings Network reports. Two research analysts have rated the stock with a ...
BioCryst Pharmaceuticals Now Covered by Analysts at JPMorgan Chase & Co ...
BioCryst Pharmaceuticals, Inc. logo JPMorgan Chase & Co. assumed coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a report issued on Friday, TheFlyOnTheWall.
Top News: BioCryst Pharmaceuticals (NASDAQ:BCRX), Time Warner Inc ...  Crazy Joys
Stocks Buzz � BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Corinthian ...  Techsonian (press release)
Related articles »  
Small Cap Stocks under bearish claws: BioCryst Pharmaceuticals, Inc. (BCRX ...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases.
Related articles »  
Most Active Buzz: BioCryst Pharmaceuticals, Inc.(NASDAQ:BCRX), CTI ...
Lakeway, NY - (MARKET NEWS CALL) - 8/05/2014�, an investment community with a special focus on updating investors with recent news on the U.S.
Related articles »